In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.

Pursuant to the terms of the Agreement, Lupin will not market its generic version of FIRDAPSE in the United States any earlier than February 25, 2035, if approved by the U.S. Food and Drug ...

With Season 4 currently in production, fans remain hopeful that Lupin Season 5 could be a possibility. It may be too early to ...

Lupin boasts a 98% Rotten Tomatoes critic score and a 79% audience score. The series was renewed by Netflix for Season 4 in ...

Omar Sy can be seen gallopping down the streets of Paris! Lupin has been in production for a good few months now across Paris ...

Catalyst Pharmaceuticals ( NASDAQ: CPRX) said that the company and licensor SERB S.A. signed a settlement agreement with ...

Lupin Limited has announced that it will seek shareholder approval via postal ballot for the re-appointment of Mr. Mark D. McDade as an Independent Director and for the revision of remuneration for Mr ...

Catalyst Pharmaceuticals agreed to settle its litigation against Lupin Pharmaceuticals over Lupin's application to market a generic version of Catalyst's Lambert-Eaton myasthenic syndrome drug.

Ranibizumab's indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration, and ...

Lupin has partnered with Swiss major Sandoz Group AG to market and commercialise Lupin’s biosimilar ranibizumab across ...

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, ...

Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 2400 in its ...